SOURCE: CDEX Inc.

May 14, 2008 09:00 ET

CDEX Inc. Announces Partnership Cooperation With International Flagship Hospitals in Europe and the Middle East

ValiMed™ Medication Validation System Is Currently Installed at Four Major Hospitals in Europe and the Middle East

TUCSON, AZ--(Marketwire - May 14, 2008) - CDEX Inc. (OTCBB: CEXI) follows up on recent announcements regarding international expansion by announcing today the installation of ValiMed at the Vall d'Hebron University Hospital in Barcelona, Spain, and at a major hospital located in Al Ain, Abu Dhabi, United Arab Emirates, for technical and clinical testing. Including the Hammersmith and Charing Cross hospitals in London, ValiMed is now installed for technical and clinical testing in four flagship hospitals across Europe and in the Middle East.

The ValiMed Medication Validation System is used both to train compounding pharmtechs/nurses and to validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety. ValiMed compares a medication's spectroscopic signature to the expected signature from the ValiMed database to detect significant medication and concentration errors as well as accidental and deliberate contamination, and provides the results in real time.

"The Vall d'Hebron University Hospital, characteristic of each of our four international cooperative partners, is one of world's most forward thinking medical facilities, is driven by excellence in patient care and has a long and impressive record in improving medication safety throughout its region," said Malcolm Philips, CDEX President and CEO. "We are honored that each of these flagship healthcare institutions has elected to partner with CDEX in testing the ValiMed system and establishing new standards and processes for patient medication safety."

About CDEX Inc.

CDEX, a technology development company currently developing products using its patented/patent pending chemical detection technologies, is focused on (i) identification of substances of concern (e.g., explosives and illegal drugs, for security markets); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of compounded medication and detection of counterfeit or sub-par products, for the medical and brand protection markets). ValiMed™ and the Meth Scanner™ are CDEX solutions for the healthcare and security markets. Corporate headquarters and R&D facilities are located in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact Malcolm Philips (mphilips@cdex-inc.com) or Pascal Pouligny (ppouligny@cdex-inc.com) at 520.745.5172.

About Vall d'Hebron University Hospital

Vall d'Hebron University Hospital, the leading hospital complex in Catalonia and one of the largest in Spain, is comprised of four large centers -- the General Area, the Maternity and Children's Area, the Trauma and Rehabilitation Area and the Outpatient Surgery Unit. The Vall d'Hebron University Hospital, with a total of more than 1400 beds strives for optimum health care delivery. More information about Vall d'Hebron Hospital can be found at http://www.vhebron.es/vhang.htm.

Any non-historical statements are forward looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other similar words. These statements pose risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed from time-to-time in filings with the SEC. There is no obligation to publicly update any forward-looking statements.

Contact Information